Cite
HARVARD Citation
Martini, A. et al. (2022). Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma. Current opinion in urology. 32 (5), pp. 500-503. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Martini, A. et al. (2022). Progression-free survival is an adequate endpoint for clinical trials of locally advanced and metastatic urothelial carcinoma. Current opinion in urology. 32 (5), pp. 500-503. [Online].